Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director

$CLVT
$CNTA
EDP Services
Technology
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $CLVT alert in real time by email

Naming the first of three business leaders for its newly created market segments and nominating new Independent Director to its Board

LONDON, March 23, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust, today announced that Gordon Samson, currently Chief Product Officer, has been appointed President of its Intellectual Property (IP) market segment, effective April 1. The Company also announced that it has nominated Dr. Saurabh Saha to stand for election as a director at its 2023 Annual General Meeting of shareholders on May 4, 2023.

Jonathan Gear, Chief Executive Officer, Clarivate said: "I'm very pleased to announce the appointment of Gordon who has been a trusted and valued member of our Executive Leadership Team since he came to Clarivate from CPA Global as part of our acquisition in 2020. In this newly created role, he will be responsible for accelerating the growth of our IP segment empowering customers to establish, protect and manage their IP.

Based on my experience working with him over the last eight months and the work we've done this year to align the organization, I'm confident that he will be instrumental to how we capitalize on product and service innovation to deliver organic growth. This is the first of our presidential appointments and we look forward to providing updates on further appointments in due course."

Samson joined Clarivate in October 2020 with the acquisition of CPA Global, having joined CPA Global in 2014 as Chief Operating Officer. During the last three years with Clarivate, Samson has made significant contributions, helping transform the Company's APAC region and bringing together the Company's entire product portfolio to offer customers a full range of enriched data, insights, analytics and workflow solutions. He has a long and successful track record of driving organizational transformation and growth in the IP industry and beyond, having held senior executive roles with both operating and P&L accountability for more than 20 years.

Andy Snyder, Chairman of the Board, Clarivate commented: "We look forward to Dr. Saha joining our Board. He will bring a great deal of experience in the pharmaceutical and biotech industries and his guidance will provide valuable insights and perspective, especially as we continue to execute on our growth strategy in the Life Sciences & Healthcare segment."

Dr. Saha is a physician-scientist, pharmaceutical executive, and biotech entrepreneur dedicated to discovering and developing novel life-changing medicines. He is notable for leading the development and demonstrating human effectiveness of two innovative cancer drugs, an ERK kinase inhibitor (Ulixertinib) and an oncolytic immunotherapy (C. novyi-NT). He is currently CEO of Centessa Pharmaceuticals (NASDAQ:CNTA), a global pharma company. Prior to Centessa, Dr. Saha was a Senior Vice President of R&D and Global Head of Translational Medicine for all disease areas at Bristol Myers Squibb. Other past roles include Venture Partner at Atlas Venture, a VC firm in Cambridge MA, Chief Executive Officer at Delinia, Chief Medical Officer of Synlogic, a management consultant at McKinsey & Company, and head of the New Indications Discovery Unit at Novartis. He is an associate member and Global Clinical Scholar at Harvard Medical School, holds an MD and PhD in medicine and cancer genetics from The Johns Hopkins School of Medicine, an MSc in biophysics from the University of Oxford and a BSc in biochemistry from Caltech.

About Clarivate

Clarivate™ is a leading global information services provider. We connect people and organizations to intelligence they can trust to transform their perspective, their work and our world. Our subscription and technology-based solutions are coupled with deep domain expertise and cover the areas of Academia & Government, Life Sciences & Healthcare and Intellectual Property. For more information, please visit clarivate.com.

Investor Relations Contact

Mark Donohue, Head of Investor Relations, investor.relations@clarivate.com, +1 (215) 243 2202

Media Contact

Amy Bourke-Waite, Senior Director, Corporate Communications, newsroom@clarivate.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/clarivate-announces-gordon-samson-as-president-intellectual-property-and-nominates-dr-saurabh-saha-as-new-independent-director-301780121.html

SOURCE Clarivate Plc

Get the next $CLVT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CLVT
$CNTA

CompanyDatePrice TargetRatingAnalyst
1/7/2025Buy
TD Cowen
11/6/2024Outperform → Mkt Perform
William Blair
9/20/2024$11.00 → $26.00Equal-Weight → Overweight
Morgan Stanley
9/19/2024$33.00Buy
B. Riley Securities
7/18/2024$14.00Outperform
Oppenheimer
12/15/2023$8.00Equal Weight → Underweight
Wells Fargo
11/15/2023$4.00 → $11.00Hold → Buy
Jefferies
10/26/2023$4.00 → $8.00Underweight → Equal-Weight
Morgan Stanley
More analyst ratings

$CLVT
$CNTA
Press Releases

Fastest customizable press release news feed in the world

See more
  • Clarivate Reveals Top 100 Global Innovators 2025

    The Top 100 organizations generate $4.6 trillion USD in annual revenues, representing 4.4% of the global economy LONDON, March 12, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today revealed its 2025 ranked list of Top 100 Global Innovators – the organizations at the forefront of technology research and innovation worldwide. The Top 100 organizations prioritize innovation as a central part of their business strategy. Their investment levels in science, engineering, product design and problem-solving is, on average, 8

    $CLVT
    EDP Services
    Technology
  • Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

    BOSTON and LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that data from the Phase 1 clinical trial of ORX750, an investigational novel highly potent and selective OX2R agonist being progressed for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), will be presented in a poster session at the American Academy of Neurology (AAN) 2025 Annual Meeting being held April 5-9, 2025, in San Diego, CA. ORX750 is being evaluated in an ongoing Phase 2a clinical trial (CRYSTAL-1

    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Clarivate Report Explores Opportunities for Innovation and Market Expansion in Latin America

    New insights from Clarivate examine strategic partnerships, API production, and innovation in the region LONDON, Feb. 27, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, has released a new white paper, How is Latin America Growing?, shedding light on the pharmaceutical industry's evolution in the region. The report explores critical challenges and opportunities, emphasizing the importance of strategic partnerships, local API production, and regulatory modernization to drive sustainable growth. Latin America's pharmaceuti

    $CLVT
    EDP Services
    Technology

$CLVT
$CNTA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CLVT
$CNTA
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$CLVT
$CNTA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CLVT
$CNTA
SEC Filings

See more

$CLVT
$CNTA
Leadership Updates

Live Leadership Updates

See more
  • Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

    BOSTON and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today announced the appointment of Stephen Kanes MD PhD, as Chief Medical Officer (CMO). Dr. Kanes is a neuropsychiatrist, with a career in neuroscience, clinical psychiatry, and neuroscience drug development spanning more than 30 years.  "Centessa is rapidly advancing a potential best-in-class and first-in-class portfolio of orexin receptor 2 (OX2R) agonists with a robust series of clinical milestones anticipated this year," said Saurabh Saha MD

    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer

    BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Financial Officer, and Gregory Weinhoff MD MBA, former Chief Financial Officer, has been appointed to the newly created role of Chief Business Officer, effective June 10, 2024. "With all three of our core programs in the clinic, we believe we have solidified a strong foundation and are poised for our next exciting chapter as a company. To best position Centessa for this pivotal time, we've added key new talen

    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Centessa Pharmaceuticals Announces Additions to Senior Leadership Team

    BOSTON and LONDON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the appointment of April Dovholuk and Ellie Im, MD to Centessa's executive team as Senior Vice President of Development Operations and Senior Vice President of Clinical Development, Oncology, respectively. In these newly created roles, Ms. Dovholuk will lead both Centessa's global Clinical Trials and Development Operations teams, and Dr. Im will manage clinical development of the Company's Oncology programs based on the LockBody® technology platform. "We a

    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CLVT
$CNTA
Financials

Live finance-specific insights

See more
  • Clarivate Reports Fourth Quarter and Full Year 2024 Results

    — Accelerates transition from transactional to subscription and re-occurring revenue — — Launches new product innovation for Academia & Government and Life Sciences & Healthcare — — Repurchased $200 million ordinary shares and pre-paid $198 million of debt in 2024 as part of balanced capital allocation strategy — — Initiates review of strategic alternatives including potential divestitures — — Provides 2025 Outlook — LONDON, Feb. 19, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the fourth quarter and full year ended December 31, 2024.

    $CLVT
    EDP Services
    Technology
  • Clarivate to Report Fourth Quarter and Full Year 2024 Results on February 19, 2025

    LONDON, Jan. 22, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, announced today it will report its financial results for the fourth quarter and full year 2024 before the market opens on Wednesday, February 19, 2025. The press release and earnings supplement, with accompanying financial information, will be available on the Clarivate investor website at https://ir.clarivate.com. The Company will host a conference call and webcast at 9:00 AM Eastern Time on Wednesday, February 19, 2025 to review the results. The webcast

    $CLVT
    EDP Services
    Technology
  • Clarivate Reports Third Quarter 2024 Results

    LONDON, Nov. 6, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Revenues of $622.2 million decreased 3.9%Organic revenues decreased 2.6%, as an increase in subscription revenues of 0.6% was offset by a decrease in re-occurring revenues of 1.1% and transactional and other revenues of 13.6%Net loss of $65.6 million; Net loss per diluted share of $0.09Adjusted net income(1) of $134.1

    $CLVT
    EDP Services
    Technology

$CLVT
$CNTA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more